Highlights
- Delta radiomics (dynamic change in features) significantly outperforms baseline or preoperative static MRI features in predicting pathological complete response (pCR) for HCC.
- The integration of temporal radiomic dynamics with serum alpha-fetoprotein (AFP) response achieved a superior AUC of 0.920 in test cohorts.
- Machine learning models utilizing deep learning-assisted feature selection provide a robust, non-invasive alternative to traditional surgical staging.
- Dynamic radiomic assessment may guide the selection of patients for hepatectomy after successful conversion therapy in initially unresectable cases.
Background
Hepatocellular carcinoma (HCC) remains one of the most lethal malignancies worldwide, often presenting at an unresectable stage (uHCC). In recent years, the treatment landscape has shifted dramatically with the introduction of conversion therapy—typically a combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs). The primary goal of conversion therapy is to downstage the tumor, enabling curative-intent hepatectomy. Within this clinical pathway, achieving a pathological complete response (pCR) is a critical surrogate marker for long-term survival. However, identifying pCR preoperatively remains a significant challenge, as conventional imaging criteria like RECIST 1.1 or mRECIST often fail to distinguish between viable tumor and necrotic/fibrotic tissue induced by immunotherapy.
There is an urgent clinical need for non-invasive biomarkers that can accurately predict pCR. While liver biochemical tests and function tests (ALT, AST, bilirubin) are essential for monitoring hepatotoxicity—especially in the context of ICI therapy—they lack the specificity required for oncological response assessment (PMID: 41831501). Radiomics, the high-throughput extraction of quantitative features from medical images, coupled with deep learning, offers a potential solution by capturing sub-visual tumor heterogeneity and its temporal evolution.
Key Content
Methodological Advances in Radiomic Dynamics
The core of recent breakthroughs in this field lies in the transition from static to dynamic imaging analysis. Traditional radiomics focuses on a single time point (e.g., baseline), which provides a snapshot of tumor biology but ignores the biological response to systemic pressure. The recent multi-center study by Zhou et al. (2026) highlights the utility of “delta radiomics”—the quantitative change in features between baseline MRI and post-treatment/preoperative MRI (PMID: 41746634).
In this framework, temporal radiomic features are extracted and processed through sophisticated machine learning pipelines. Feature selection typically involves univariate analysis, collinearity assessment, and Least Absolute Shrinkage and Selection Operator (LASSO) regression. Benchmarking across multiple machine learning models (including random forests and deep learning architectures) has shown that delta features capture the “radiomic trajectory” of a tumor, which is more representative of therapeutic sensitivity than any single-point measurement.
Clinical Outcomes: Delta vs. Baseline Models
The evidence demonstrates a clear hierarchy in predictive performance. In the validation cohorts for uHCC patients undergoing conversion therapy, delta radiomic models achieved an Area Under the Curve (AUC) of approximately 0.783 to 0.835. In stark contrast, baseline models (AUC ~0.434–0.483) and preoperative models (AUC ~0.506–0.685) performed poorly, often slightly better than chance. This suggests that the initial state of the tumor is a poor predictor of how it will ultimately respond to immunotherapy, and that the pre-surgery scan alone may be obscured by treatment-induced inflammatory changes.
The Synergistic Role of AFP Response
Beyond imaging, biochemical markers remain vital. Alpha-fetoprotein (AFP) is the most widely used biomarker for HCC. By calculating the AFP response as a logarithmic ratio of preoperative to baseline levels, clinicians can integrate biological activity with morphological changes. The synthesis of delta radiomics and AFP response has shown the highest predictive accuracy to date. Specifically, a combined model achieved an AUC of 0.920 in internal testing and 0.857 in independent validation cohorts (PMID: 41746634). This synergy suggests that while radiomics captures spatial heterogeneity, AFP response provides a global measure of the tumor’s secretory activity, creating a comprehensive profile of the pathological state.
Translational and Comparative Context
While experimental murine models (PMID: 41825745) continue to provide insights into the immunopathological and molecular features of virus-associated HCC, clinical radiomics bridges the gap between these mechanistic studies and real-world patient care. Unlike liver stiffness evaluations used in MASLD (PMID: 41831487), which primarily assess fibrosis, tumor radiomics specifically interrogates the neoplastic environment. Furthermore, as we move toward individualized HCC surveillance (PMID: 41813085), the ability to predict pCR non-invasively may allow some patients to avoid the morbidity of major surgery if a complete response can be confirmed with near-certainty, or conversely, identify those who require more aggressive adjuvant strategies.
Expert Commentary
The shift from qualitative image interpretation to quantitative radiomic modeling represents a paradigm shift in surgical oncology. From a clinical perspective, the superiority of delta radiomics over preoperative static imaging is logical; immunotherapy often results in “pseudoprogression” or stable radiological size despite significant pathological necrosis. Therefore, the change in internal texture (radiomic signature) is a more faithful reporter of cell death than tumor diameter.
However, several challenges remain. The first is the “black box” nature of deep learning; many clinicians find it difficult to trust a model without understanding which biological features the AI is identifying. Second, radiomics is highly sensitive to imaging protocols, requiring rigorous standardization across different MRI scanners and institutions. The study by Zhou et al. is notable for its multi-center design, which addresses some concerns regarding generalizability, but further prospective validation is required before these models can be integrated into national guidelines (e.g., AASLD or ESMO). Future research should also explore the integration of radiomics with liquid biopsy (circulating tumor DNA) to further enhance predictive specificity.
Conclusion
The integration of deep learning and dynamic radiomic analysis marks a significant advance in the management of uHCC. By focusing on the delta—the change in tumor character over the course of conversion therapy—clinicians can predict pCR with high precision (AUC > 0.90 when combined with AFP). This non-invasive approach facilitates personalized treatment decisions, potentially identifying patients who have achieved a complete response prior to the first incision. As AI tools become more refined and standardized, they will likely become indispensable adjuncts to traditional imaging in the oncology clinic.
References
- Zhou SQ, Wang LN, Wu LF, et al. Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy. Hepatology. 2026. PMID: 41746634.
- Evaluation of Abnormal Liver Biochemical Test Results. Gastroenterology. 2026. PMID: 41831501.
- An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma. J Hepatol. 2026. PMID: 41825745.
- Steatosis severity and metabolic fingerprints after HCV eradication: toward an individualised approach to HCC surveillance after HCV cure. Gut. 2026. PMID: 41813085.
